The systemic vasculitides are a heterogeneous group of disorders characterized by inflammation of blood vessel walls. They can be classified according to the size of vessel affected and also into primary de novo vasculitides and secondary to other disease processes. Treatments differ and overlap depending on the type of vasculitis. It is therefore important to make the correct diagnosis and treat appropriately to achieve remission as there is a substantial mortality implication.
Oien RF, Hakansson M, Hansen BU.Leg ulcers in patients with rheumatoid arthritis—a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatology2001;40(7):816-820.
2.
Jennette JC, Falk RJ, Andrassy K, et al.Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum1994;37(2):187-192.
3.
Hunder GG, Arend WP, Bloch DA, et al.The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum1990;33:1065.
4.
Jover JA, Hernandez-Garcia C, Morado IC, et al.Combined treatment of giant cell arteritis with methotrexate and prednisolone. A randomised double blind placebo controlled trial. Ann Intern Med2001;134(2):106-114.
5.
De Silva M, Hazleman BL.Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double blind study. Ann Rheum Dis1986;45(2):136-138.
6.
Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, et al.Takayasu’s arteritis. Clinical study of 107 cases. Am Heart J1977;93(1):94-103.
7.
Kerr GS, Hallahan CW, Giordano J, et al.Takayasu’s arteritis. Ann Intern Med1994;120(11):919-929.
8.
Hoffman M, Corr P, Robbs J.Cerebrovascular findings in Takayasu’s disease. J Neuroimaging2000;10(2):84-90.
9.
Kato T, Kakuta T, Maruyama Y, et al.QT dispersion in patients with Takayasu’s arteritis. Angiology2000;51(9):751-756.
10.
Hall S, Barr W, Lie JT, et al.Takayasu’s arteritis. A study of 32 North American patients. Medicine1985;64(2):89-99.
11.
Hoffman GS, Leavitt RY, Kerr GS, et al.Treatment of glucocorticoid resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum1994;37(4):578-582.
12.
Daina E, Schieppati A, Remuzzi G.Mycophenolate mofetil for the treatment of Takayasu arteritis: report of 3 cases. Ann Intern Med1999;130(5):422-426.
13.
Numano F, Okawara M, Inomata H, et al.Takayasu’s arteritis. Lancet2000;356(9234):1023-1025.
14.
Watts RA, Joliffe VA, Carruthers DM, et al.Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum1996;39(7):1208-1212.
15.
Guillevin L, Lhote F, Gayraud M, et al.Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine1996;39:17-28.
16.
Gayraud M, Guillevin L, Cohen P, et al.Treatment of good prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. Br J Rheumatol1997;36:1290-1297.
17.
Trepo C, Ouzan D, Delmont J, et al.Supériorité d’un nouveau traitement etiopathogenique curateur des periarteritis noueuses induites par le virus de l’hepatite B grauce a l’association corticotherapie breve, vidarabin, echanges plasmatiques. Presse Med1988;17:1527.
18.
Guillevin L, Lhote F, Cohen P, et al.Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine1995;74:238-253.
19.
Frohnert PP, Sheps SG.Long-term follow-up study of polyarteritis nodosa. Am J Med1979;43:8-14.
20.
Guillevin L, Jarrousse B, Lok C, et al.Long-term follow-up after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomised trial of 71 patients. J Rheumatol1991;18:567-574.
21.
Kawasaki T.Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes. Jpn J Allergy1967;16:178.
22.
Durongpisitkul K, Gururaj VJ, Park JM, et al.The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Paediatrics1995;96:1057.
23.
Tidman M, Olander R, Svalander C, et al.Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med1998;244(2):133-141.
24.
Lie JT.Wegener’s granulomatosis: histological documentation of common and uncommon manifestations in 216 patients. Vasa1997;26(4):261-270.
25.
Storesund B, Gran JT, Koldingsnes W.Severe intestinal involvement in Wegener’s granulomatosis: report of two cases and review of the literature [Review]. Br J Rheumatol1998;37(4):387-390.
26.
Walton E.Giant cell granuloma of the respiratory tract (Wegener’s granulomatosis). BMJ1958;2:265-270.
27.
Fauci A, Wolff S.Wegener’s granulomatosis: studies in eighteen patients and a review of the literature. Medicine1973;52:535-561.
28.
Fauci AS, Haynes BF, Katz P, et al.Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med1983;98:76-85.
29.
Talar-Williams C, Hijazi YM, Walther MM, et al.Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener’s granulomatosis. Ann Intern Med1996;124:477-484.
30.
Hoffman GS, Leavitt RY, Fleisher TA, et al.Treatment of Wegener’s granulomatosis with intermittent high dose intravenous cyclophosphamide. Am J Med1990;89:403-410.
31.
Reinhold-Keller E, Kekow J, Schnabel A, et al.Influence of disease manifestation and antineutrophil cytoplasmic antibody titre on the response to pulse cyclophosphamide therapy in patients with Wegener’s granulomatosis. Arthritis Rheum1994;37:919-924.
32.
Guillevin L, Cordier JF, Lhote F.A prospective, multicentre randomised trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalised Wegener’s granulomatosis. Arthritis Rheum1997;40:2187-2198.
33.
de Groot K, Muhler M, Reinhold-Keller E, et al.Induction of remission in Wegener’s granulomatosis with low dose methotrexate. J Rheumatol1998;25:492-495.
34.
Stone JH, Tun W, Hellman DB.Treatment of non-life-threatening Wegener’s granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol1999;26:1134-1139.
35.
de Groot K, Reinhold-Keller E, Tatsis E, et al.Therapy for the maintenance of remission in sixty-five patients with generalised Wegener’s granulomatosis. Methotrexate versus trimethoprim/sulphamethoxazole. Arthritis Rheum1996;39:2052-2061.
36.
Stone JH, Uhlfelder ML, Hellman DB, et al.Etanercept combined with conventional treatment in Wegener’s granulomatosis. A six month open label trial to evaluate safety. Arthritis Rheum2001;44:1149-1154.
37.
Langford CA, Talar-Williams C, Barron KS, et al.Phase I/II trial of etanercept in Wegener’s granulomatosis (WG): safety and preliminary experience. ACR 64th meeting, Philadelphia, PA, Abstract 577 [127201].
38.
Lockwood CM.Refractory Wegener’s granulomatosis: a model for shorter immunotherapy of autoimmune disease. J R Coll Physicians Lond1998;32(5):473-478.
39.
Jayne DR, Lockwood CM.Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol1996;35(11):1150-1153.
40.
Gordon M, Luqmani RA, Adu D, et al.Relapses in patients with a systemic vasculitis. Q J Med1993;86:779.
41.
Guillevin L, Gain O, Lhote F, et al.Lack of superiority of steroids plus plasma exchange to steroids alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome: a prospective randomised trial in 78 patients. Arthritis Rheum1992;35:208.
42.
Gross WL.New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol1999;11(1):41.
43.
Voskuyl AE, Zwinderman AH, Westedt ML, et al.Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis1996;55(3):190-192.
44.
Voskuyl AE, Zwinderman AH, Westedt ML, et al.The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum1996;39(2):266-271.
45.
Lie JT.Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Clin North Am1990;16:269-292.
46.
Heurkens AH, Westedt ML, Breedveld FC.Prednisolone plus azathioprine treatment in patients with rheumatoid arthritis complicated by vasculitis. Arch Intern Med1991;151:2249-2254.
47.
Barwell JR, Ghauri ASK, Taylor M, et al.Risk factors for healing and recurrence of chronic venous leg ulcers. Phlebolgy2000;15(2):49-52.
48.
Tuveri M, Generini S, Matucci-Cerinic M, Aloe L.NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. Lancet2000;356(9243):1739-1740.
49.
Lambiase A, Rama P, Bonini S, Capriogolo G, Aloe L.Topical treatment with nerve growth factor for corneal neurotropic ulcers. N Engl J Med1998;23:1174-1180.
